Loading

Please wait...

Arcalyst

Generic Name: rilonacept (ril ON a sept)
Brand Names: Arcalyst
Arcalyst (rilonacept) is used to treat Familial Cold Auto-inflammatory Syndrome or Muckle-Wells Syndrome. Includes Arcalyst side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Arcalyst

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Arcalyst (riloNacept) is used to treat some of the symptoms of rare genetic conditions such as Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS). FCAS and MWS are inflammatory disorders in which the body develops certain symptoms without a known cause (such as virus, bacteria, or illness). These symptoms include fever, chills, fatigue, and joint pain. More serious symptoms may involve the bones and joints, the central nervous system (deafness, vision loss, mental impairment), or major organs such as the kidneys. Learn more

Arcalyst Side Effects

Arcalyst Side Effects

Note: This document contains side effect information about rilonacept. Some of the dosage forms listed on this page may not apply to the brand name Arcalyst.

In Summary

Common side effects of Arcalyst include: upper respiratory tract infection and injection site reaction. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to rilonacept: subcutaneous powder for solution

Along with its needed effects, rilonacept (the active ingredient contained in Arcalyst) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking rilonacept:

More common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at site
  • body aches or pain
  • chills
  • cough
  • difficulty in breathing
  • ear congestion
  • fever
  • headache
  • loss of voice
  • nasal congestion
  • runny nose
  • sneezing
  • sore throat
  • unusual tiredness or weakness

Incidence not known

  • Bloody or black, tarry stools
  • constipation
  • cough producing mucus
  • lower back or side pain
  • pain or tenderness around eyes and cheekbones
  • painful or difficult urination
  • severe stomach pain
  • shortness of breath or troubled breathing
  • tenderness
  • tightness of chest or wheezing
  • vomiting of blood or material that looks like coffee grounds

Some side effects of rilonacept may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings

Less common

  • Stomach discomfort

For Healthcare Professionals

Applies to rilonacept: subcutaneous powder for injection

Local

Very common (10% or more): Injection site reactions (e.g., erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, hemorrhage) (48%)

In patients with Cryopyrin-Associated Periodic Syndromes (CAPS), the most common and consistently reported adverse event associated with rilonacept was injection-site reaction (ISR). The ISRs included erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, and hemorrhage. Most injection-site reactions lasted for one to two days. No ISRs were assessed as severe, and no patient discontinued study participation due to an ISR.

Immunologic

One subject receiving rilonacept (the active ingredient contained in Arcalyst) for an unapproved indication developed an infection in his olecranon bursa with Mycobacterium intracellulare. The patient was on chronic glucocorticoid treatment. The infection occurred after an intraarticular glucocorticoid injection into the bursa with subsequent local exposure to a suspected source of mycobacteria. The patient recovered after the administration of the appropriate antimicrobial therapy.

A patient treated for another unapproved indication developed bronchitis/sinusitis, which resulted in hospitalization.

One patient died in an open-label study of CAPS from Streptococcus pneumoniae meningitis.

Very common (10% or more): Infection (34%)

Respiratory

Very common (10% or more): Upper respiratory tract infection (26%)

Common (1% to 10%): Sinusitis, cough

Nervous system

Common (1% to 10%): Hypoesthesia

Gastrointestinal

Common (1% to 10%): Nausea, diarrhea, stomach disorder

Hematologic

The patient did not experience any infection associated with the neutropenia.

Physicians should monitor the lipid profiles of their patients (for example after 2 to 3 months) and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.

Frequency not reported: Neutropenia

Genitourinary

Common (1% to 10%): Urinary tract infection

Hypersensitivity

Rare (less than 0.1%): Hypersensitivity

Metabolic

Frequency not reported: Increased mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides (in patients with CAPS)

General

The most commonly reported adverse reaction is injection-site reaction (ISR). The next most commonly reported adverse reaction is upper respiratory infection.

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Arcalyst (www.drugs.com/arcalyst.html).